A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)
Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This two-part study will evaluate the effectiveness of etoricoxib in controlling pain in
participants with osteoarthritis who are experiencing inadequate response to their current
treatments. In Part 1, all participants will receive open-label etoricoxib 60 mg daily. Those
participants who experience a clinically meaningful response to etoricoxib 60 mg daily within
two weeks will be eligible to enter the double-blind withdrawal period (Part II). Responders
entering Part 2 will be randomized in a 1:1 ratio to receive either etoricoxib 60 mg or
placebo.